Phreesia’s (PHR) “Outperform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reiterated their outperform rating on shares of Phreesia (NYSE:PHR) in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a $19.00 target price on the stock.

Other analysts have also issued research reports about the stock. Truist Financial boosted their price target on shares of Phreesia from $11.00 to $12.00 and gave the company a “hold” rating in a research report on Thursday, May 28th. Weiss Ratings raised shares of Phreesia from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, July 20th. Canaccord Genuity Group reiterated a “buy” rating and issued a $16.00 price objective on shares of Phreesia in a research note on Thursday. Piper Sandler cut shares of Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 target price on the stock. in a report on Thursday, May 28th. Finally, Barclays restated an “equal weight” rating and set a $10.00 target price (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $15.25.

Phreesia Trading Down 1.2%

Shares of PHR opened at $10.97 on Thursday. The business has a 50-day moving average of $11.25 and a 200 day moving average of $10.47. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $30.43. The firm has a market cap of $678.06 million, a P/E ratio of 64.53 and a beta of 0.86. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.76 and a current ratio of 1.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings data on Wednesday, September 2nd. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.06). The firm had revenue of $129.46 million during the quarter, compared to the consensus estimate of $129.06 million. Phreesia had a net margin of 2.06% and a return on equity of 5.35%. The company’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.01 earnings per share. As a group, research analysts forecast that Phreesia will post 0.38 EPS for the current year.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently bought and sold shares of the company. Pale Fire Capital SE boosted its holdings in Phreesia by 3.2% in the 2nd quarter. Pale Fire Capital SE now owns 8,924,329 shares of the company’s stock valued at $91,831,000 after purchasing an additional 275,000 shares during the period. BlackRock Inc. purchased a new stake in shares of Phreesia in the second quarter worth $72,234,000. Vanguard Group Inc. raised its position in shares of Phreesia by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock worth $97,194,000 after buying an additional 39,540 shares in the last quarter. Granahan Investment Management LLC boosted its stake in Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after buying an additional 1,018,987 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Phreesia by 28.8% during the fourth quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock valued at $33,841,000 after buying an additional 446,890 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: RBC Capital reiterated a Buy rating on Phreesia, supporting the investment case despite recent earnings pressure. Phreesia Receives a Buy from RBC Capital
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and assigned a $19 price target, while Canaccord Genuity reaffirmed its Buy rating with a $16 target. The targets imply substantial upside from the recent trading level and indicate analysts remain confident in Phreesia’s longer-term prospects.
• Positive Sentiment: Second-quarter fiscal 2027 revenue increased approximately 10% year over year to $129.5 million, slightly exceeding consensus expectations. Adjusted EBITDA reached $32.9 million, highlighting continued operating profitability and scale. Phreesia Q2 Fiscal 2027 Revenue Rises 10 Percent
• Neutral Sentiment: Analyst commentary remains constructive, but the wide gap between current trading levels and price targets suggests the market is waiting for clearer evidence that Phreesia can accelerate earnings growth.
• Negative Sentiment: Phreesia reported quarterly EPS of $0.03, below the consensus estimate of $0.09. The earnings shortfall overshadowed the revenue beat and likely drove the negative investor reaction. Phreesia Shares Sink After 2Q Earnings Underwhelm

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.